Science topic
Cancer Research - Science topic
Explore the latest questions and answers in Cancer Research, and find Cancer Research experts.
Questions related to Cancer Research
Hello, so me and my partner started our 6 weeks cancer research project into CACO-2 cells and testing extra cellular vesicles by plating. We are on day 3 and all was going well until today, we refreshed the media in the T75 flask and centrifuge of the sample. We added the sample to the incubator and came back today and half of the heathy cells had died and didn’t adhere back to the flask which we thought was unusual. We found these cells to be stuborn and in order to break the clusters we needed 8 minutes of tryspin. Has anybody done a similar experiment before and encountered these issues Or have some suggestions to try and maintain the healthy cells. Many thanks!
Basic knowledge of DNA Damage Reponses (DDR) and their functional integration with the therapeutically relevant immune responses are fundamentally advancing cancer biology and medicine. The 7th DNA Replication/Repair Structures & Cancer Conference (7th DRRSC) February 24-28 2026 will bring together scientists to exchange cutting-edge research findings and stimulate new ideas and approaches to address the critical challenges in cancer research. Conference talks and discussions will center on developing actionable mechanistic knowledge of DNA replication, transcription and repair stress responses and their inflammation impacts suitable to guide cancer research and intervention for biology and medicine.
To interject some reality into current U.S. government actions on NIH research overhead, I seriously doubt there are any biomedical research efforts of any useful quality in the US that could function on 15% overhead. This 15% idea sounds good to those who know little about research, but unfortunately it goes against facts, reason, logic, and law.
The various NIH requirements for accounting and many other compliance rules likely cost far more than 15%. Furthermore, buildings need to be heated, cooled and maintained. People need to be hired and managed. Cold rooms, warm rooms, and equipment need power and computing infrastructure. Most companies estimate their overhead on research as ~100%, and this is in fact the overhead charged at US National labs subject to lengthy DOE negations. So an enforced change to 15% NIH overhead would mark the end of quality US biomedical research as we know it now.
If the US remains a country of laws, then I predict that this 15% notion cannot happen any time soon. Legally this is an unconstitutional act as it changes congress appropriations and illegally breaks negotiated contracts for funded grants. If laws do not matter here, then Texas has thrown away billions for CPRIT and any meaningful cancer research will largely be done in other countries. Time will tell but statements made by current US leadership have not proven durable.
Near term, I guess that a 15% enforced overhead will mean the loss of our top scientists. This will cost the US many orders of magnitude more than the overhead they imagine saving somehow. Of course, this would also quickly end the pipeline from innovative research to products for US companies and be a boon to US competitors while losing billions in biomedical economy for the U.S. Perhaps money will speak if laws do not?
What do you think?
Format: (Vancouver reference style)
Presenter(s). Title of presentation [type of presentation]. Presented at: Conference Name; Date; Location.
Example:
Smith J, Johnson A. Advances in cancer research [oral presentation]. Presented at: Annual Oncology Conference; 2023 Mar 15-17; New York, USA.
Recently, many AI tools have been developed for cancer research, including, but not limited to, diagnosis and treatment. Therefore, providing specific guidance may help the research community advance their interests.
Im trying to work out if a drug Im using in vitro is synergistic with radiation. The majority of online synergy calculators allow you to calculate synergy with 2 drugs in the same units, but not a drug with radiation. I have a Mac computer and ideally want to use an online calculator of some sort.
Is there software or an online calculator I can use?
I tried to download compusyn but it doesn't seem to be compatible with a Mac.
kindly check my ResearchGate profile
Hi Researchers,
I hope you all doing great in science. I am Ihtisham Ul haq, and I have a master's degree in microbiology.
I am interested in the biorisk management of different developed and emerging technologies. I am planning to pursue my doctorate in the field of biosafety in cancer research. However, I am struggling to clearly understand the relationship between biosafety and cancer research.
That's why I am posting this question here if you people have any good suggestions for me, I would be very grateful.
I am also available on ihaq@bs.qau.edu.pk
Hi,
I am trying to established ex vivo organoid culture from normal mouse ovaries. I started the culture 7 days ago and I got to see some sferes. However, I when I passed them I observed that I did not manage to see aggregates again. I am surprised because I see a lot of cells and they seem to be alive. I was thinking that maybe cell density is too high or that I have a problem with the media. I am preparing home-made media according to the protocol descrobed in Zhang et al., Cancer Research (2019).
This is the picture of how cells look after 48h post-passaging.
Hi guys I am facing an issue regarding spatial transcriptomics. Let's say I am preparing a PPFE for a patient sample. I am only interested in the cancer cells in the tissue. Just from the eye, I can't tell where the cells are located/ which dimension I should fix it for PPFE / cut for microtome. What are some good practices for us to help with getting a good microtome slide with tumor cells for spatial transcriptomic analysis? :'')
I would like to stably knockdown my GOI in the E0771 cell line (mouse breast cancer), which I will then inject into mice to establish a tumour-bearing model. However, I have never done this before and also don't know a lot about the techniques involved. So far, I figured out that I need to transfect my cells with a viral vector expressing either shRNA or miRNA targeting my GOI, and that the viral vector I use needs to be able to integrate into the host genome.
Is this correct? What would be the best option for me to use? What steps/techniques does this procedure require (to generate a vector like capable of this)?
The vector also needs to have some kind of reporter in as well (eg GFP) because I need to be able to visualize tumour growth and metastasis over time (live animal imaging).
what are the top 3 challenges to the advancement of the field of Radiogenomics in cancer research? is it the availability of easily available low-cost matched imaging and biosamples with clinical history?
how can I eslablish Biobank unit for cancer research is there any funder can help?
📢📢📢 Call for Papers: Memorial Issue to Prof. Kazuo Umezawa: A Noteworthy Biochemistry Educator
📅📅 Submission Deadline: 31 December 2024
💫💫 Research Field: NF-κB, Immunology, Biochemistry, Cancer Research, Apoptosis
💡💡 Contact: christyhe99@gmail.com
Welcome your comments~
Dear Colleagues and friends,
as Co-Chairman, I would like to invite you to join us and present your work at the VII INTERNATIONAL CANCER IMMUNOTHERAPY CONFERENCE (CICON23) – TRANSLATING SCIENCE INTO SURVIVAL, which will be held in Milan from September 20th to 23rd, 2023.
Launched in 2015, under the patronage of the Cancer Research Institute (CRI), the American Association for Cancer Research (AACR), and the European Network for Cancer Immunotherapy (ENCI), the Conference continues to provide groundbreaking discoveries, being the ideal place to promote the fast- moving field of immunology and immunotherapy.
We have assembled a line-up of outstanding speakers, including the Nobel Laureate Jim Allison together with Arlene Sharpe, Tony Ribas, Lisa Coussens, Nir Hacohen, Padmanee Sharma, Ozlem Tureci, Laurance Zitvogel, and Shannon Turley just to name a few. At the same time, we dedicated slots for talks selected from the best abstracts, opportunities for short oral posters presentations, and ample time to discuss the data.
Our goal is to provide an exciting and unique opportunity for all attendees, students, postdocs and PIs, to meet top scientists and talk with colleagues in an informal environment.
Some additional information about the Scientific and Social Program could be found on the site, http://www.cancerimmunotherapyconference.org/program-of-events
You can submit your abstracts here: http://www.cancerimmunotherapyconference.org/abstracts, till the 15th of June, 2023, so, please, use your chance and submit your abstract now!
For registration please go to http://www.cancerimmunotherapyconference.org/registration.
We particularly encourage students and postdocs to attend the conference and, in order to facilitate their presence, we offer special registration rates and travel bursaries, which can be applied for during the abstract submission., so, get your ticket now for the early bird price!
If you have any questions or need further information, please do not hesitate to contact me.
I look forward welcome you at the COCON23!
Best regards
Dr. Pier Francesco Ferrucci
Chair CICON23,
President of the Italian Network Tumor Bio-immunotherapy (NIBIT),
Scientific Director Grazia Focacci Foundation,
SEMM Faculty,
Director of Tumor Biotherapy Unit,
IEO - Istituto Europeo di Oncologia - IRCCS
Via Ripamonti 435 - 20141 Milano, Italia
T: +39 02 94371094 E: pier.ferrucci@ieo.it W: http://www.ieo.it/it/CHI-SIAMO/Come-siamo-organizzati/Le-divisioni/Unita-di-Bioterapia-dei-Tumori-BTTUN/
If this message does not display properly, please click here to view it online in your browser
ABSTRACT SUBMISSION DEADLINE JUNE 15, 2023
We are excited to announce the organization of a research topic titled "Big Data and Machine Learning in Urological Cancer Research: Exploring New Treatment Targets and Strategies Using Big Data Analysis and Machine Learning Algorithms" for publication in Frontiers in Genetics.
This topic aims to delve into the transformative potential of big data and machine learning in advancing urological cancer research. We seek to explore novel treatment targets and strategies, leveraging the vast possibilities offered by these advanced technologies.
We are in search of one more researcher to join our organizing team who meets the following criteria:
- H-index Over 15: The researcher should have an H-index greater than 15, indicating a significant impact in their field of study.
- No Retracted Publications: The researcher should have a clean record of publication, with no history of retracted publications.
- Non-China Based Affiliation: The researcher's primary affiliation should be outside of China.
This is a unique opportunity to contribute to a pioneering field and collaborate with experts in genetics, big data analysis, and machine learning.
Responsibilities of the Collaborator:
- Contribute to the conceptualization and framing of the research topic.
- Assist in the process of inviting submissions, reviewing manuscripts, and editing content.
- Engage in promoting the research topic within academic and professional networks.
Application Process:
Interested researchers are invited to contact us with a brief overview of their academic background and a statement of interest. Please include details of your H-index and a link to your professional or academic profile.
Contact Information:
Yuxuan Song
In some studies (especially cancer research), a relevant cell line (e.g. endometrial cell line) is used in cell culture together with an unrelated cell line (e.g. kidney cell line). However, the unrelated cell line is not used in all subsequent experiments. What is the reason for this?
Do I have to use different cell lines in my study?
Hello everyone,
I have just started using Olympus fluoview for confocal microscopy and I don't know much about microscopy. I plate my cells (HeLa) in 4 welled Chambers slide. Stain the cells with Mito tracker dye, fix it with 4% PFA, wash, add mounting media and do the microscopy. The first time everything was fine. The second time I was trying to optimize the dye concentration, but something went wrong. The microscope kept on showing 'The focus position not found in scanned containers'. I had two slides and both of them had the same problem. When I tried with my old slide, it was fine. I have no clue what is wrong with my slide. All the chemicals and reagents that I have used is same as before except for PFA. The second time I diluted 8% PFA with sodium phosphate buffer to get 4% PFA. Can PFA cause problem finding focus?
When a woman is diagnosed with breast cancer, the difficult question arises as to which type of treatment is the right one. Gene expression testing is one of the methods used by doctors to help make a prognosis about the course of the disease and, based on this, to select a suitable therapy. However, the reliability of these tests has not been fully established. Scientists from Leipzig University and the Pathologie Hamburg-West institute have now used machine learning to analyse large amounts of data on this question and found that gene expression signatures offer a high degree of certainty in prognosis, but not complete certainty.
Gene expression signatures are descriptions of the activity patterns of genes. When a person is diagnosed with cancer, these signatures can be used to make predictions about how tumours will develop. As such, they are crucial for classifying different types of cancer, determining prognosis and defining treatment strategies.
The current study by Dimitrij Tschodu, a doctoral researcher at the Peter Debye Institute for Soft Matter Physics at Leipzig University, was carried out in close collaboration with Professor Axel Niendorf from the Pathologie Hamburg-West institute and was recently published in the renowned journal Scientific Reports. Tschodu and his colleagues analysed around 10,000 signatures based on renowned breast cancer databases using various machine learning models to thoroughly assess their prognostic ability.
The results of the study show that the gene expression signatures examined lead to a correct patient prognosis in no more than 80 per cent of cases. The researchers also point out that prognoses based on gene expression signatures alone take into account less than 50 per cent of the potentially available information. They therefore recommend using other parameters in addition to gene expression tests. “Although our results confirm the importance of gene expression signatures in predicting patient prognosis, they also highlight the urgent need for a holistic approach that takes into account molecular, clinical, histological and other complementary factors to ensure an accurate prognosis,” explains Tschodu.
Need for a holistic approach to prognosis
“The results of this study are crucial for understanding the limitations of gene expression signatures in cancer prognosis,” adds Professor Josef Käs, head of the Soft Matter Physics Division at Leipzig University. “While gene expression signatures are undoubtedly valuable, our findings show that a holistic approach is needed to ensure an accurate prognosis and to make informed decisions about treatment.”
The publication comes from the Physics of Cancer research field, which looks at cancer from a physical perspective and also examines the mechanics of cells and tissues. Käs says: “This new study underlines the importance of the ‘Physics of Cancer’ in the medical field and the need for interdisciplinary collaboration to find innovative solutions to the challenges in cancer treatment.” Only recently, a research group led by Professor Käs and Professor Niendorf published new findings in this field that could promote more precise diagnostics of the spread and formation of metastases in breast tumours.
Original title of the publication in Scientific Reports: “Re-evaluation of publicly available gene-expression databases using machine-learning yields a maximum prognostic power in breast cancer”, DOI: https://doi.org/10.1038/s41598-023-41090-9
In the ever-evolving landscape of #livercancer research, staying updated with the latest findings and breakthroughs is crucial for researchers and clinicians alike. To aid you in this journey, we've curated a list of seven outstanding articles published in #OncologyResearch that shed light on diverse aspects of hepatocellular carcinoma (#HCC). These articles encompass cutting-edge discoveries, innovative methodologies, and critical insights that are shaping the field of liver cancer research.
More updated insights are welcome to contribute to us!
Breast cancer continues to pose a significant global challenge to women's health. Fortunately, with the continuous progress in science and technology, our understanding of the disease and treatment methods has been deepening. As a dedicated cancer research journal, Oncology Research is committed to disseminating the latest advancements in breast cancer research. Our goal is to empower patients, physicians, and researchers with the knowledge necessary to better understand and respond to this serious disease.
Over the past two years, we have proudly published a series of pivotal breast cancer research papers, showcasing exceptional work from renowned scientists worldwide. With rigorous screening, our team has curated a selection of significant papers on breast cancer published between 2022 and 2023. These articles encompass a wide range of aspects, including early diagnosis, personalized treatment, immunotherapy, and more. By delving into these innovative studies, we aim to provide valuable insights into breast cancer development, novel treatment approaches, and preventive strategies.
Join us in exploring these cutting-edge research findings, enabling us to collectively advance our knowledge and make meaningful progress in combating breast cancer.
01.Has_circ_0000069 expression in breast cancer and its influences on prognosis and cellular activities
GANG WANG, MINGPING QIAN, WEI JIAN, JUHANG CHU, YIXIANG HUANG*
02.An inflammatory-related genes signature based model for prognosis prediction in breast cancer
JINGYUE FU, RUI CHEN, ZHIZHENG ZHANG, JIANYI ZHAO, TIANSONG XIA*
03.Targeting triple-negative breast cancer: A clinical perspective
LAZAR S. POPOVIC*, GORANA MATOVINA-BRKO, MAJA POPOVIC, KEVIN PUNIE, ANA CVETANOVIC, MATTEO LAMBERTINI
04.Senescent mesenchymal stem/stromal cells in pre-metastatic bone marrow of untreated advanced breast cancer patients
FRANCISCO RAÚL BORZONE*, MARÍA BELÉN GIORELLO, LEANDRO MARCELO MARTINEZ, MARÍA CECILIA SANMARTIN, LEONARDO FELDMAN, FEDERICO DIMASE, EMILIO BATAGELJ, GUSTAVO YANNARELLI, NORMA ALEJANDRA CHASSEING*
05.The role of AFAP1-AS1 in mitotic catastrophe and metastasis of triple-negative breast cancer cells by activating the PLK1 signaling pathway
SHUIZHONG CEN, XIAOJIE PENG, JIANWEN DENG, HAIYUN JIN, ZHINAN DENG, XIAOHUA LIN, DI ZHU, MING JIN6, YANWEN ZHU, PUSHENG ZHANG, YUNFENG LUO, HONGYAN HUANG*
06.Integrative multiomics analysis identifies a metastasis-related gene signature and the potential oncogenic role of EZR in breast cancer
GUODONG XIAO, FENG CHENG1, JING YUAN1, WEIPING LU1, PEILI WANG2, HUIJIE FAN1*
07.circRNAs in drug resistance of breast cancer
SEMA MISIR*, SERAP OZER YAMAN, NINA PETROVIĆ, CEREN SUMER, CEYLAN HEPOKUR, YUKSEL ALIYAZICIOGLU
08.The Implication of microRNAs as non-invasive biomarkers in 179 Egyptian breast cancer female patients
NADIA Z. SHAABAN, NASHWA K. IBRAHIM, HELEN N. SAADA, FATMA H. EL-RASHIDY, HEBATALLAH M. SHAABAN, NERMEEN M. ELBAKARY*, AHMAD S. KODOUS*
Thank you for your time.
Sincerely,
Oncology Research Editorial
Contact Us:
871 Coronado Center Drive, Suite 200,
Henderson, Nevada, 89052, US
Tel: +1 702 673 0457
Fax: +1 844 635 2598
Office Hours: 9:00-17:00 (UTC -8:00)
Anyone knows name of a journal for cancer research where I can publish freee of cost or low cost.
Dear Colleagues and friends,
as Co-Chairman, I would like to invite you to join us and present your work at the VII INTERNATIONAL CANCER IMMUNOTHERAPY CONFERENCE (CICON23) – TRANSLATING SCIENCE INTO SURVIVAL, which will be held in Milan from September 20th to 23rd, 2023.
Launched in 2015, under the patronage of the Cancer Research Institute (CRI), the American Association for Cancer Research (AACR), and the European Network for Cancer Immunotherapy (ENCI), the Conference continues to provide groundbreaking discoveries, being the ideal place to promote the fast- moving field of immunology and immunotherapy.
We have assembled a line-up of outstanding speakers, including the Nobel Laureate Jim Allison together with Arlene Sharpe, Tony Ribas, Lisa Coussens, Nir Hacohen, Padmanee Sharma, Ozlem Tureci, Laurance Zitvogel, and Shannon Turley just to name a few. At the same time, we dedicated slots for talks selected from the best abstracts, opportunities for short oral posters presentations, and ample time to discuss the data.
Our goal is to provide an exciting and unique opportunity for all attendees, students, postdocs and PIs, to meet top scientists and talk with colleagues in an informal environment.
Some additional information about the Scientific and Social Program could be found on the site, http://www.cancerimmunotherapyconference.org/program-of-events
You can submit your abstracts here: http://www.cancerimmunotherapyconference.org/abstracts, till the 15th of June, 2023, so, please, use your chance and submit your abstract now!
For registration please go to: http://www.cancerimmunotherapyconference.org/registration.
We particularly encourage students and postdocs to attend the conference and, in order to facilitate their presence, we offer special registration rates and travel bursaries, which can be applied for during the abstract submission., so, get your ticket now for the early bird price!
If you have any questions or need further information, please do not hesitate to contact me.
I look forward welcome you at the COCON23!
Best regards
Dr. Pier Francesco Ferrucci
Chair CICON23,
President of the Italian Network Tumor Bio-immunotherapy (NIBIT),
Scientific Director Grazia Focacci Foundation,
SEMM Faculty,
Director of Tumor Biotherapy Unit,
IEO - Istituto Europeo di Oncologia - IRCCS
Via Ripamonti 435 - 20141 Milano, Italia
T: +39 02 94371094 E: pier.ferrucci@ieo.it W: http://www.ieo.it/it/CHI-SIAMO/Come-siamo-organizzati/Le-divisioni/Unita-di-Bioterapia-dei-Tumori-BTTUN/
ABSTRACT SUBMISSION DEADLINE JUNE 15, 2023
Hi,
I have been having difficulties in monitoring CAF activation because the lung fibroblasts Wi-38 that I am using seem to already have high levels of expression of a-SMA, FAP and PDGFRb, according to my Western Blot. I am not sure if it has to do with the origin of the cells or the cell culture conditions that are activating them. Any guidance will be greatly appreciated!
I have been culturing 293T cells since last 2 years and never had this issue. They develop multiple vesicles seeding after 2-3 days, fail to grow and degenerate. I have tried changing media with fresh cells, but with same results. Are they infected or some other deficiency ? Kindly refer to the attached pics.
Other than "The Cancer Proteome Atlas (TCPA)" (https://tcpaportal.org/tcpa/index.html), which other cancer-based databases/tools can be used to associate a list of genes to identify different types of cancer.
I've used a drug that I am suspecting increases cell migration. I've got data of area at 0 hour and 24h of a scratch assay. I've got many replicates but can't seem to figure out the best strategy for statistical analysis. Any suggestion with some brief explanation?
Hello PCa research community,
I am searching for an appropriate prostate epithelial cell line to use as a non-cancerous, non-tumorigenic, control for my PCa experiments. I came across the RWPE-1 cell line as a commonly used control in my literature reviews. I cannot seem to find it being sold on any of the well known vendors (ATCC, Sigma, etc). Does anyone who works with this cell line know of where I can reliably purchase a vial?
Alternatively, ff anyone is willing to share a vial with our research group, we'd also be incredibly grateful!
All the best,
Isaac
I got an invitation through email to attend this conference. Exaggerated statements like "The entire World Cancer 2023 team is enthusiastic about your work" made me suspicious of this conference and if it is another spam. Anyone has an experience can tell us about this conference?
@bobkeller
Thanks
I am using propidium iodide (Hi-media Product) but i want to know how much Concentration of propidium iodide is required to stain in 100 cells ?
A few years ago I moved from my job as a biologist in a research institute to a private research manager.
Right now I'm looking for ideas on how to collaborate with other researchers in academic institutions.
I have experience in lateral flow, immunology and cancer research.
Currently my main asset is my experience and I eager to do research again.
I'm passionate in oncology research. I did bachelor in Zoology and now pursuing MPhil Molecular Biology and Biotechnology and working on cancer genetics. I am greatly interested to do PhD in cancer research from a world renowned institute but I think with this profile I would get a position in top ranked institute for PhD. Should I go for another master from a renowned foreign institute with major in oncology?
Thanks
I am curious about the average quality of PhD research proposals, especially those with cancer research as a focus. Any suggestions, guidance, tricks, or words of wisdom?
Thank you.
Hello! I was doing a cancer research and also became interested in stem cell these days. But since I don't know much things about stem cell, I wanna study about the relationship between stem cell and cancer.
I think I heard that there are quite much relationship between them but don't know what are they.
Can someone tell me about it or recommend some papers related to this?:)
Hi friends,
So I'm new to cell culturing research and synthetic biology and I'm working with MDA-MB-231 cells. Fairly regularly I have to at least split plates in order to maintain the cells, but I am also passaging cells for other things. Normally on a 10cm petri dish I'd plan to seed ~5.0E5 cells/mL for regular splitting and in a 96 well plate I'd seed ~4.5E4 cells/mL for my experiments. One thing I'm confused on still is using the hemocytometer to calculate cell density because I'm not entirely sure what my dilution factor should be.
Normally, I'll remove the old media, wash with PBS then trypsinize cells, after incubating for 5mins I add a bit more media until the total volume is 10mL, then I spin everything down. After that, I aspirate out the supernatant and am left with a small pellet of cells that I then break up and dilute with ~2-6mL of fresh media before using the hemocytometer to count the number of cells in 10uL.
My question is since I'm removing all the old media after centrifugation but then am adding new (different amount) media prior to counting, how does that impact the overall dilution factor?
Here's an example of what I was taught to do to find the amount of cells in 1mL, I just wanted to confirm that I'm on the right track. I was told if I resuspended my pellet in 3mL of media and then counted 75 cells I'd have:
75 cells/10E-4mL media
75 E4 cells/1mL media
7.5E5 cells/1mL media --> multiply this by 3 since you used 3mL to dilute before counting to get total number of cells (is this what accounts for the dilution factor?)
Total of 2.25E-6 cells that could be split however you see fit? Sometimes determining how many plates to get out can feel like a guessing game. Let me know if you see any issues with my method or suggestions that might be helpful, I welcome them. Please do try to be kind as I'm still learning and figuring things out. Thank you.
Kylie
I am analysing several drugs on tumour cell lines. I need a quick way to calculate IC50 based on data generated.
Could you please provide any tips or ideas you have for creating the finest meta analysis review on cancer? Rather than writing a review article, I'd like to begin working on a meta analysis.
regards
We want to know if one protein can be used as a breast cancer biomarker or not. So we'll have to compare normal and patients, and our question is whether we can get samples from patients who received chemotherapy before?
I should use the BCH for inhibition experiment for LAT1. I saw that BCH is soluble in 1M NH4OH but I cannot use this solution with cells.
in cancer therapy, sometimes you have to target multi-targets to understand the molecular pathway of the specific protein. CHyMErA can target multi targets but it is not safe and has a high risk of extra mutation!
Is there a chance for cancer research fields, such as exponential growth of infected blood cells methodology, to be related to COVID-19 research generally?
This seminal paper by Paul Mischel rediscovered the relationship between extrachromosal DNA (ecDNA) and cancer:
1. How much would it cost to replicate the part of the experiment that generated subcutaneous tumors from seeds containing 200/2000/20000 cells of FACS-sorted EGFRvIII High/EGFRvIII Low subpopulations?
2. How much would it cost to sequence these tumor cells?
Thanks for your help!
Hi
I'm trying to design a simple cube-shaped DNA origami with specific dimensions from just single stranded DNA oligos.
Since there is no specific scaffold the origami is based on, cadnano is difficult to use...
I understand you can use Nupack... but I'm not sure how to create 3d objects using Nupack.
Would there be a better program fit for this or what would be the ways doing so in nupack?
Permissible limit of arsenic in drinking water was 50 μg/l by WHO which was later reduced to 10 μg/l. Currently many countries like Bangladesh and China have not updated their own Permissible limits. However, this is been observed that on the event of long term exposure of arsenic at low concentration that is less then 10 μg/l in drinking water, health complication arises.
I made a stock solution (25mM) of Pioglitazone hydrochloride (Tocris) in DMSO. It has dissolved finely. Then I treated the cells maintained in serum free DMEM with a final concentration of 100 micromoler of Pioglitazone. Here it forms crystals, precipitates in the culture vessel, but I am not getting the desired effect of it on the cells. Please suggest how to achieve the proper effect of Pioglitazone treatment?
I don't have a solution, bur we also see hair-like crystals forming in our culture media when pioglitazone concentration ≥10µM.
I want DNA microarray cancer data sets with features and samples to form a gene expression matrix for applying intelligence techniques (such as basiayan neural network algorithm) to classify cancer data sets. Please help me.
There is an increasing amount of research on the ketogenic diet in cancer therapy. However, I can't find much about this diet in those guidelines produced by governmental cancer research institutes such as American Institute for Cancer Research (AICR). As a matter of fact it seems like the word ketogenic is totally missing from the databases.
Am I missing something?
National Library of Medicine results: https://pubmed.ncbi.nlm.nih.gov/?term=ketogenic+diets+cancer
Sincerely Yours,
Christer Sundqvist
PhD Helsinki
The main ‘party trick’ of cancer stem cell (CSC) seem to be that it provide another explanation for tumour heterogeneity (i.e. cell divide asymmetrically give rise to progeny cells that are different). Secondly, asymmetric cell division is what makes this model ‘useful’ (i.e. clinically relevant): CSC model refer to a subpopulation of cells that must be targeted for effective thematic outcome. But if asymmetric cell division does not take place (i.e. if all cells divide symmetrically) than any therapy that kill cancer is in fact targeting the CSC (i.e. there is no point in identifying CSC- each cell would be one under symmetric cell division).
So, is asymmetric cell division a hallmark of CSC model? Any good literature on this?
Hi!
I am trying to find a good immunocompetent mouse model to study triple negative breast cancer (TNBC). The 4T1-BALB/c model is perhaps not ideal for studies on immunosuppression and as 4T1 is derived from BALB/c mice, it cannot be transplanted in the C57BL/6 strain. Can someone suggest a good animal model to study TNBC-induced immunosuppression?
I'm using the BrdU antibody of the roche kit but i can't see any signal.
I had a contaminated cell culture I suspected several things, including the media. I put the media (only) in a T-25 flask and used 2 agar plates to check bacterial contamination (one opened in the laminar air flow the other in the CO2 incubator) and left them is in the CO2 incubator at 37 oC (after I cleaned it),
two days later I didn't find any thing on the agar plates and no changes in color or clarity of the media in flask however I examined the flask under the microscope and found these things .. What could it be?
I am working with rectal swab samples in the field of colorectal cancer research. Does anyone have experience (or can point towards any relevant literature) of specifically working with proteins (extraction, characterization, or anything even remotely connected to protein work) in rectal swab samples (or any mucosal swab samples).
Thank you!
I just asking cancer expertise to suggestions the best books can read by MSc students before start their PhD program in cancer research
I'm fairly new to cancer research and there's a host of articles on Sunitinib being administered via oral gavage in mice models but I'm unable to find any information on studies that have explored directly injecting tumors with Sunitinib. Just curious.
Hello Everyone,
I've been writing a review article (almost done) on cancer research. Is anyone interested in collaborative writing and publication? Please let me know. We can share our ideas on extending the content of the paper and get it published mutually.
Professionals with an interest in cancer research are most welcome.
Thanks,
Dr. Ranbir
I currently doing a research for anticancer drugs and have a plan to use CA 15-3 as tumor marker to measure the effectivity. Some reference tell that CA 15-3 and MUC 1 are synonym, but i also found some reference that stated CA 15-3 and MUC are different. My question is "Could I use ELISA kit for MUC 1 to measure the CA 15-3?" because my local supplier can't find the ELISA kit for CA 15-3 in affordable price.
I read many papers about exosome isolation from fresh blood or frozen plasma, but not for frozen whole blood. I am wondering whether can I get exosomes from cryopreserved whole blood? One of my workmate told me the blood cells were broken if crypreserved and would affect the isolation of exosomes? What I need is the exosomes and their surface biomarkers. Could anyone give me your prescious advices? thank you so much.
when i was working in hood for cell culture, i forget to turn off the UV light .
1.is the UV light within less than 30 minutes leads cell damage for example SKBR3, or MCF10A ?
2. is the medium also affected with this situations? thank you
Could anybody please tell me what are the different types of cells that originate from HNSCC patient samples. What are the type of studies that it can be used for?
I understand there are epithelial, fibroblasts, and keratinocytes that can be derived from HNSCC tumor samples. Can immunological studies be done using these type of cells?
I am looking for a scientifically oriented internet site providing new research in the category of cancer treatments.
I isolated a large amount (I hope) of exosomes and I need to quantify the membrane proteins with a Bradford assay before doing a WB. I started off with 70 ml of conditioned medium which I managed to concentrate to about 1 ml before ultracentrifugation. After ultracentrifugation I added 200 ul PBS to my samples. My expectation is that the concentration of exosomes is quite high. So now I need to do a Bradford assay and I would like to know how to dilute my samples.
Hello,
I am new to cancer research and I am trying to optimize my small cell lung cancer cell protocol.
I purchased a cell line from ATCC (H1105) and I have been growing the cells in RPMI 1640 media (10% FBS + penicillin/streptomycin.
I am looking for anyone who was worked with these cells in the past and who can let me know if these cells look normal?
I noticed the cells grow very slowly and form spheres.
Am I using the right media? How can I get the cells to grow faster? Can someone refer me to a good SCLC cell culture protocol? Thank you.
I need to confirm a knockdown of HER2 in SKBR3 and BT474 cells, have had problems blotting for HER2 in the past so any advice with regards to the protocol or antobody choice is much appreciated, thanks
For my cancer research, I am doing cell culture with HPNE and MIA PACA. So, I would like to know the answer.
I am studying on cancer research and ı used bcl 2 antibody to understand there is apoptosis or not. I got good band ı tested with ponceu red. Finally I got this result.ı used uvp chemi doc it2 imager to preview membrane.I tried a lot of times what do you think about this result?
Tumor suppressor genes (such as Rb, APC, PTEN and the ever famous p53) are often downregulated in cancer cells, if not completely lost or dysfunctional.
I'd like to know if there are any tumor suppressor genes that are upregulated in metastatic cancer cell lines/models? If so, could you link to articles/publications/studies of such genes? Are these genes bi-modal? Or have people figured out the molecular mechanism behind these genes?
I'd appreciate any and all help provided.
Thank you.
Hi everyone
I am planning to use the Qiagen RT2 Profiler PCR array for signaling pathways. Is it really necessary to use the RT2 SYBR Green Mastermixes and the RT2 First Strand Kit with the profiler array? Can I use Applied Biosystems SYBR Green PCR mastermix instead (Cat no. 4309155) as well as my already synthesized cDNAs? The platform is Roche Light Cycler 480.
Looking forward for some help. Many thanks.
Dear friends and colleagues,
there is a very important resource on the web that is "Atlas of Genetics and Cytogenetics in Oncology and Haematology". The Atlas is a peer reviewed on-line journal / encyclopedia / database established in 1997 that collects data about cancer genes, solid tumors, leukaemia and other resources. It is in open free access for readers and there are no fees for the authors.
I'm searching volunteers and collaborators that would to write with me reviews about single genes involved in cancer.
I have published several papers so far and I believe that Atlas is a very valuable tool for us researchers, scientists and scholars.
I invite you to visit the Atlas website at http://atlasgeneticsoncology.org/index.html for more information. Here is my latest article published http://atlasgeneticsoncology.org//Genes/GC_EEF1B2.html to show you my working method. Anyone wishing to collaborate with me to write a specific review on a gene can tell me as well.
Which colorectal cell lines that has c-Met overexpression or amplification, dose anyone has any related literature please send me
recently I am working on a project about the effect of bio-luminescence in cancer research. It would be my honor and pleasure to help me on this way
The event of death by metastasis or recurrence is very common, many researchers have linked the tendency of some tumors to re-appear to the presence of occult or dormant cancer cells that may have a phenotype that allows them to remain "hidden" from the immune response. However, the understanding of these cells and the mechanisms that they use to achieve evasion remain mostly unknown. It is critical to understand these cells better and to be able to detect their presence for they are of great therapeutic importance.
Cancer is very dangerous disease and allopathy drugs are unable to treat. Phyto-constituents of Lady's finger may act against this.
There are a lot of published data that showed association between vitD deficiency and many disorders e.g. diabetes, metabolic syndrome, CVD, cancer,...
To write a captivating, motivating and scientifically attractive application, what are the needed tips to have one?.
I am looking for information concerning the effect of publications regarding 5-year survival of diseases, like cancer, on the feelings of the patient. As the statistics are frequently published, and available on many websites with information on serious diseases, I was wondering whether psychological research was done as to the impact these statistics have on patients, dealing with diseases. I have tried to find such research myself, but the overwhelming majority of research I have found deals solely with diagnostic importance of these analysis. I will be most thankful for any advice and references on this issue.
several old studies says no, more recent studies says yes. Robert Bell in 1870 used raw salad to increase amygdalin in cancer patients and used saliva to detect the presence. Several sources say amygdaline converts to cyanide in an acidic enviroment and when gets in contact with acid lactic of cancer masses convert to cyanide and kill them (sort of selective killing). To be absorbed as amygdaline and avoid convertion into cyanide in the gut it should be taken from food rather administered directly. There are some roman texts about incresing lifespan of cancer patients with regular intake of 2-3 bitter almonds (rich on amygdaline) a day. Anyone has experience on it? Are research on amygdaline extensive and satisfactory? What is your opinion?
An exogenous RNA molecule is involved in the pathogenesis of cancer and transfered cancer among animals. It is living organism.
Can anyone suggest me the precise and new anti-cancer target for docking of peptide type compounds. As per literature reports the chemical class of the above peptides are mitotic inhibitors. The BAX and BID along with Caspase 3 were highly expressed with peptides while in cytotoxicity studies. When the above genes are over expressing (Biomarkers) is an indication of apoptosis. Can I choose Caspase 3 as druggable target for these compounds and go for docking ?
Cancer research has developed precise biomarkers to use a proper cure for different kind of cancers. Why there is no proper biomarker to find the precise treatment in autoimmune desease, such as psoriatic arthritis?
Since humanized and SCID mice are very expensive to procure and maintain. I was wondering to develop a cost and effective approach to develop an in vivo model for cancer research. Thymectomy is well established method to cause immunosuppression. I was wondering what will happen if we try to develop PDX model in thymectomized alone or in combination with immunosuppressants in C57bl/6 or Balb/c mice. Will tumor model be developed ?
I woul like to submit a Review article in the Journal of Cancer Research and Clinical Oncology. Are there publication fees for this Journal?
Thank you in advance!!
We are trying to test some formulations of PD1 antibody on cancer models and would like to have a robust in vitro technique for future in vivo assessments.
Most studies on CAR-T cells use NSG mice (B/T cell deficient) based on the papers I found. Only a few use nude mice (T cell deficient, B cell present), which is what we are hoping to do. Does anyone have experience with using nude mice tumor model in CAR-T cell studies? What are the problems with using nude mice for CAR-T cell studies (since B cell is APC), and what are the potential solutions? Thanks a lot for any responses!
In my job, I transient transfected Active-wnt3a construct into Hek293T and Hek293 for expression , I collected three batch(fresh medium 5ml in 10cm dish for 24hr)
conditioned medium and concentrated in 500 µl ,but it didnt have any effect when it treatment 20µl for TopFlash repoter assay!!!!
Can any one tell me what can i do?
I have submitted a manuscript to clinical cancer research and the status changed to "decision pending" on the same day "under review". And I wonder whether it is not good news, how long will I receive the email from the editor?
We are looking for highly motivated candidates to join our lab. More info available in the link below:
Any help with spreading the word about them will be highly appreciated.
Hello! For my study assignment (cancer research, up/downregulation of a gene in high and low density cells) the standard deviation is not necessary but we think it is important to put in our short communication. We found out that the standard deviation is taken from the delta-CT value. For example: you have a gene of interest and a reference gene. Each gene is done in triplo and you have a control and a treatment.
GOI control: 32.37, 31.76, 31.80
Ref control: 16.05, 15.10, 15.76
GOI treatment: 30.1, 29.78, 29.88
Ref control: 18.56, 15.64, 14.76
We've calculated the delta-CT from the averages of the measured values. How can I calculate the standard deviation for the delta-CT value?
Thanks in advance for your help.
I'm a Research associate at 57357 hospital , Egypt , I would like to ask about two cell lines : RD , RH30 ( Rahbdomyosarcoma ) we couldn't find them in Egypt and we are committed to certain budget , deadlines and masters thesis based on this project , anyone know a trusted source or a lab in any country usually uses them to give as aliquot ? Thank you in advance !
What could we change in preparing tissue samples prior cryosections(cryostat) method for more convenience and results? ( I mean cryo-embedding) The second question is in which areas of research do you use this one and why is it a pretty rare method of imaging? It is interesting to get answers from researchers who are working currently with this method or those who worked with that recently.
Thank All in advance for any ideas.
I'm starting to work on microRNA profile in a mouse model of liver cancer. We would like to use the next generation of sequencing approaches since it enables mapping and quantification of all transcripts.
Since it is the first time we are working with sequencing, I was wondering if somebody could suggest the best company to contact. I was in contact with LC Science because a colleague of mine recommended them. We are also evaluating the Arraystar sequencing service. Does anyone have some suggestions or recommendations for other companies?
To fight the disease effectively, researchers from across the scientific spectrum and beyond must join forces.
